SOUTH SAN FRANCISCO, CA--(Marketwire - Dec 4, 2012
Post# of 28539
Posted On: 12/04/2012 4:10:06 PM
SOUTH SAN FRANCISCO, CA--(Marketwire - Dec 4, 2012) - Theravance, Inc. (NASDAQ: THRX) announced today the initiation of a fibromyalgia Phase 2 study with TD-9855, the lead compound in Theravance's Monoamine Reuptake Inhibitor program. TD-9855 is an investigational norepinephrine and serotonin reuptake inhibitor (NSRI) for the treatment of central nervous system (CNS) conditions such as chronic pain and Attention-Deficit/Hyperactivity Disorder (ADHD).
(0)
(0)